Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.
Matsubara N, Kusuhara S, Yamamoto N, Sudo K, Yanagita M, Murayama K, Kawasumi H, Russell DL, Yin D, Shimizu T. Matsubara N, et al. Among authors: shimizu t. Cancer Chemother Pharmacol. 2024 Apr;93(4):341-352. doi: 10.1007/s00280-023-04605-9. Epub 2023 Dec 13. Cancer Chemother Pharmacol. 2024. PMID: 38086998 Free PMC article.
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
Kitano S, Fujiwara Y, Shimizu T, Iwasa S, Yonemori K, Kondo S, Shimomura A, Koyama T, Ebata T, Ikezawa H, Hayata N, Minoshima Y, Miura T, Kubota T, Yamamoto N. Kitano S, et al. Among authors: shimizu t. Cancer Chemother Pharmacol. 2022 Dec;90(6):523-529. doi: 10.1007/s00280-022-04480-w. Epub 2022 Oct 26. Cancer Chemother Pharmacol. 2022. PMID: 36289094 Clinical Trial.
FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.
Fujiwara Y, Kuboki Y, Furukawa M, Mizuno N, Hara H, Ioka T, Ueno M, Takahashi Y, Takahashi S, Takeuchi S, Lihou C, Ji T, Tian C, Shimizu T. Fujiwara Y, et al. Among authors: shimizu t. Cancer Med. 2023 May;12(9):10597-10611. doi: 10.1002/cam4.5798. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 37000035 Free PMC article. Clinical Trial.
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
Yamamoto N, Koyama T, Shimizu T, Todaka A, Kawakami T, Erzen D, Sarashina A, Li B, Hou J, Yamazaki K. Yamamoto N, et al. Among authors: shimizu t. Cancer Chemother Pharmacol. 2023 Jun;91(6):469-480. doi: 10.1007/s00280-023-04527-6. Epub 2023 May 4. Cancer Chemother Pharmacol. 2023. PMID: 37140602 Clinical Trial.
Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) study.
Nishino M, Fujimori M, Koyama T, Hirata M, Tanabe N, Shimizu T, Yamamoto N, Uchitomi Y. Nishino M, et al. Among authors: shimizu t. PLoS One. 2023 May 26;18(5):e0283968. doi: 10.1371/journal.pone.0283968. eCollection 2023. PLoS One. 2023. PMID: 37235572 Free PMC article.
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. Heist RS, et al. Among authors: shimizu t. Cancer Treat Rev. 2024 Apr;125:102720. doi: 10.1016/j.ctrv.2024.102720. Epub 2024 Mar 11. Cancer Treat Rev. 2024. PMID: 38502995 Free article. Review.
A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies.
Curigliano G, Jimenez MM, Shimizu T, Keam B, Meric-Bernstam F, Rutten A, Glaspy J, Schuler PJ, Parikh NS, Ising M, Hassounah N, Wu J, Leyk M, Chen X, Burks H, Chaudhury A, Otero J, Cabanas EG. Curigliano G, et al. Among authors: shimizu t. ESMO Open. 2024 Aug;9(8):103643. doi: 10.1016/j.esmoop.2024.103643. Epub 2024 Jul 31. ESMO Open. 2024. PMID: 39088985 Free PMC article. Clinical Trial.
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
Peterlin P, Saada-Bouzid E, Moskovitz M, Pigneux A, Yuda J, Sinnollareddy M, Henner WR, Chen D, Freise KJ, Leibman RS, Avigdor A, Shimizu T. Peterlin P, et al. Among authors: shimizu t. Expert Rev Anticancer Ther. 2024 Sep;24(9):893-904. doi: 10.1080/14737140.2024.2373888. Epub 2024 Jul 10. Expert Rev Anticancer Ther. 2024. PMID: 38946484 Clinical Trial.
10,340 results
You have reached the last available page of results. Please see the User Guide for more information.